On January 4, 2024 Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, reported the Company’s plans for its emerging sarcoma franchise including projections for peak US sales of up to $400 million (Press release, Adaptimmune, JAN 4, 2024, View Source [SID1234638960]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will present plans for the franchise at the JP Morgan Healthcare Conference on January 11th from 8:15 to 8:55 a.m. PST at the Westin, San Francisco. The presentation will be webcast and a replay will be available at the same link.

Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer: "2024 is the year Adaptimmune transforms into a commercial cell therapy company with the anticipated approval and launch of afami-cel, the first asset in our sarcoma franchise. By 2026, we plan to have two marketed cell therapies for sarcoma. These therapies will redefine the treatment paradigm for people with sarcoma and are projected to deliver US peak sales of up to $400m. Our sarcoma franchise has tremendous upside with potential for expansion and is only the beginning of our solid tumor cell therapy aspirations."